Abstract
Introduction Understanding COVID-19 vaccine effectiveness (VE) in healthcare workers (HCWs) is critical to inform vaccination policies. We measured COVID-19 VE against laboratory-confirmed symptomatic infection in HCWs in the country of Georgia from January – June 2022, during a period of Omicron circulation. Methods We conducted a cohort study of HCWs in six hospitals in Georgia. HCWs were enrolled in early 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT). Participants were also routinely tested, at varying frequencies during the study period, for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected quarterly throughout the study and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We estimated absolute and relative VE of a first booster dose compared to a primary vaccine series as (1-hazard ratio)*100 using Cox proportional hazards models. Results Among 1253 HCWs, 141 (11%) received a primary vaccine series (PVS) and a first booster, 855 (68%) received PVS only, and 248 (20%) were unvaccinated. Most boosters were BNT162b2 (Comirnaty original monovalent) vaccine (90%) and BBIBP-CorV vaccine (Sinopharm) (9%). Most PVS were BNT162b2 vaccine (68%) and BBIBP-CorV vaccine (24%). Absolute VE for a first booster was 40% (95% Confidence Interval (CI) -56–77) at 7–29 days following vaccination, -9% (95% CI -104–42) at 30–59 days following vaccination, and -46% (95% CI -156–17) at≥60 days following vaccination. Relative VE of first booster dose compared to PVS was 58% (95% CI 1–82) at 7–29 days following vaccination, 21% (95% CI -33–54) at 30–59 days following vaccination, and -9% (95% CI -82–34) at≥60 days following vaccination. Conclusion In Georgia, first booster dose VE against symptomatic SARS-CoV-2 infection among HCWs was moderately effective but waned very quickly during Omicron. Increased efforts to vaccinate priority groups in Georgia, such as healthcare workers, prior to periods of anticipated high COVID-19 incidence are essential.
| Original language | English |
|---|---|
| Article number | e0311337 |
| Journal | PLoS ONE |
| Volume | 20 |
| Issue number | 5 MAY |
| DOIs | |
| Publication status | Published - May 2025 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
